Document Detail


Spasticity in multiple sclerosis: results of a Spanish patient survey.
MedLine Citation:
PMID:  23297730     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Information regarding the epidemiology of spasticity in patients with multiple sclerosis (MS) in Spain is limited. This cross-sectional survey-based study was undertaken to evaluate the symptoms, severity and consequences of MS-related spasticity (MSS), and to estimate the prevalence of MSS overall and according to the degree of severity (mild/moderate/severe). Adult MS patients (n = 8463) from the two main Spanish MS patients' associations were asked to complete a web-based questionnaire. 2627 responses were received of which 2029 were valid for analysis. Two-thirds were for women. The mean age of respondents was 40.2 years and the mean MS duration was 8.7 years. MSS was reported by 65.7% of respondents with 40% of these rating it as moderate/severe. MS patients with spasticity experienced more symptoms (including greater difficulty walking), consumed more healthcare resources (including care and rehabilitation sessions), and had a higher degree of disability than patients without spasticity. There was a significant correlation between increasing severity of spasticity and worsening of symptoms. Only 42.4% of patients with moderate spasticity and 52.6% of patients with severe spasticity were currently receiving antispasticity medication compared with 69% and 79%, respectively, reported in a similar survey-based study from the US; this is likely to reflect regional variations in practice. Early and effective treatment of MSS is important to minimise the consequences of spasticity-related symptoms on patients' quality of life and the economic burden on healthcare systems. In appropriate patients, antispastic treatment including pharmacotherapy and physiotherapy/rehabilitation may provide such benefits. An overview of the 6E study was presented as a poster at the 5th Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS). 19-22 October 2011, Amsterdam, The Netherlands.
Authors:
C Oreja-Guevara; D González-Segura; C Vila
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-9
Journal Detail:
Title:  The International journal of neuroscience     Volume:  -     ISSN:  1563-5279     ISO Abbreviation:  Int. J. Neurosci.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0270707     Medline TA:  Int J Neurosci     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Multiple Sclerosis Unit, Neurology, University Hospital San Carlos; IdISSC , Madrid , Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Characterization of enteric neurons in wild-type and mutant zebrafish using semi-automated cell coun...
Next Document:  Quantification of carbonic anhydrase gene expression in ventricle of hypertrophic and failing human ...